Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'ACTIVE METABOLITE SN-38' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 33 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Oguma, T
      Antitumor drugs possessing topoisomerase I inhibition: applicable separation methods

      JOURNAL OF CHROMATOGRAPHY B
    2. Palumbo, M; Sissi, C; Gatto, B; Moro, S; Zagotto, G
      Quantitation of camptothecin and related compounds

      JOURNAL OF CHROMATOGRAPHY B
    3. Zufia, L; Aldaz, A; Giraldez, J
      Separation methods for camptothecin and related compounds

      JOURNAL OF CHROMATOGRAPHY B
    4. Ong, SYK; Clarke, SJ; Bishop, J; Dodds, HM; Rivory, LP
      Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction

      ANTI-CANCER DRUGS
    5. Boyd, G; Smyth, JF; Jodrell, DI; Cummings, J
      High-performance liquid chromatographic technique for the simultaneous determination of lactone and hydroxy acid forms of camptothecin and SN-38 in tissue culture media and cancer cells

      ANALYTICAL BIOCHEMISTRY
    6. Ratain, MJ
      Insights into the pharmacokinetics and pharmacodynamics of irinotecan

      CLINICAL CANCER RESEARCH
    7. Pitot, HC; Goldberg, RM; Reid, JM; Sloan, JA; Skaff, PA; Erlichman, C; Rubin, J; Burch, PA; Adjei, AA; Alberts, SA; Schaaf, LJ; Elfring, G; Miller, LL
      Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride(CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy

      CLINICAL CANCER RESEARCH
    8. Loos, WJ; de Bruijn, P; Verweij, J; Sparreboom, A
      Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography

      ANTI-CANCER DRUGS
    9. Takimoto, CH; Morrison, G; Harold, N; Quinn, M; Monahan, BP; Band, RA; Cottrell, J; Guemei, A; Llorens, V; Hehman, H; Ismail, AS; Flemming, D; Gosky, DM; Hirota, H; Berger, SJ; Berger, NA; Chen, AP; Shapiro, JD; Arbuck, SG; Wright, J; Hamilton, JM; Allegra, CJ; Grem, JL
      Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients

      JOURNAL OF CLINICAL ONCOLOGY
    10. Couteau, C; Risse, ML; Ducreux, M; Lefresne-Soulas, F; Riva, A; Lebecq, A; Ruffie, P; Rougier, P; Lokiec, F; Bruno, R; Armand, JP
      Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors

      JOURNAL OF CLINICAL ONCOLOGY
    11. Vanhoefer, U; Achterrath, W; Wilke, H; Seeber, S
      Preclinical evaluation of irinotecan

      ONKOLOGIE
    12. Jansman, FGA; Sleijfer, DT; Coenen, JLLM; De Graaf, JC; Brouwers, JRBJ
      Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer

      DRUG SAFETY
    13. Boisdron-Celle, M; Boulanger, N; Gamelin, E
      Pharmacokinetic monitoring

      BULLETIN DU CANCER
    14. Pommier, Y; Pourquier, P; Urasaki, Y; Wu, JX; Laco, GS
      Topoisomerase I inhibitors: selectivity and cellular resistance

      DRUG RESISTANCE UPDATES
    15. Mathijssen, RHJ; van Alphen, RJ; de Jonge, MJA; Verweij, J; de Bruijn, P; Loos, WJ; Nooter, K; Vernillet, L; Stoter, G; Sparreboom, A
      Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin

      ANTI-CANCER DRUGS
    16. Ducreux, M; Ychou, M; Seitz, JF; Bonnay, M; Bexon, A; Armand, JP; Mahjoubi, M; Mery-Mignard, D; Rougier, P
      Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): A clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer

      JOURNAL OF CLINICAL ONCOLOGY
    17. Wasserman, E; Cuvier, C; Lokiec, F; Goldwasser, F; Kalla, S; Mery-Mignard, D; Ouldkaci, M; Besmaine, A; Dupont-Andre, G; Mahjoubi, M; Marty, M; Misset, JL; Cvitkovic, E
      Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: Results of two independent phase I studies with pharmacokinetics

      JOURNAL OF CLINICAL ONCOLOGY
    18. de Bruijn, P; de Jonge, MJA; Verweij, J; Loos, WJ; Nooter, K; Stoter, G; Sparreboom, A
      Femtomole quantitation of 7-ethyl-10-hydroxycamptothecine (SN-38) in plasma samples by reversed-phase high-performance liquid chromatography

      ANALYTICAL BIOCHEMISTRY
    19. RIVORY LP; FINDLAY M; CLARKE S; BISHOP J
      TRACE ANALYSIS OF SN-38 IN HUMAN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY

      Journal of chromatography B. Biomedical sciences and applications
    20. HERBEN VMM; HUININK WWT; SCHELLENS JHM; BEIJNEN JH
      CLINICAL PHARMACOKINETICS OF CAMPTOTHECIN TOPOISOMERASE-I INHIBITORS

      Pharmacy world & science
    21. HECHT JR
      GASTROINTESTINAL TOXICITY OF IRINOTECAN

      Oncology
    22. IYER L; RATAIN MJ
      CLINICAL-PHARMACOLOGY OF CAMPTOTHECINS

      Cancer chemotherapy and pharmacology
    23. INABA M; OHNISHI Y; ISHII H; TANIOKA Y; YOSHIDA Y; SUDOH K; HAKUSUI H; MIZUNO N; ITO K; SUGIYAMA Y
      PHARMACOKINETICS OF CPT-11 IN RHESUS-MONKEYS

      Cancer chemotherapy and pharmacology
    24. TAKIMOTO CH; WRIGHT J; ARBUCK SG
      CLINICAL-APPLICATIONS OF THE CAMPTOTHECINS

      Biochimica et biophysica acta, N. Gene structure and expression
    25. SIU LL; ROWINSKY EK
      A RISK-BENEFIT ASSESSMENT OF IRINOTECAN IN SOLID TUMORS

      Drug safety
    26. ARBUCK SG; TAKIMOTO CH
      AN OVERVIEW OF TOPOISOMERASE-I - TARGETING AGENTS

      Seminars in hematology
    27. ROBERT J; RIVORY L
      PHARMACOLOGY OF IRINOTECAN

      Medicamentos de actualidad
    28. Chabot, GG; Robert, J; Lokiec, F; Canal, P
      Irinotecan pharmacokinetics

      BULLETIN DU CANCER
    29. YAMAMOTO N; TAMURA T; NISHIWAKI Y; KURITA Y; KAWAKAMI Y; ABE S; NAKABAYASHI T; SUZUKI S; MATSUDA T; HAYASHI I; TAKAHASHI T; SAIJO N
      LIMITED SAMPLING MODEL FOR THE AREA UNDER THE CONCENTRATION VERSUS TIME CURVE OF IRINOTECAN AND ITS APPLICATION TO A MULTICENTRIC PHASE-II TRIAL

      Clinical cancer research
    30. GUPTA E; MICK R; RAMIREZ J; WANG XL; LESTINGI TM; VOKES EE; RATAIN MJ
      PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION OF THE TOPOISOMERASE INHIBITOR IRINOTECAN IN CANCER-PATIENTS

      Journal of clinical oncology
    31. CHABOT GG
      CLINICAL PHARMACOKINETICS OF IRINOTECAN

      Clinical pharmacokinetics
    32. OREILLY S; ROWINSKY EK
      THE CLINICAL STATUS OF IRINOTECAN (CPT-11), A NOVEL WATER-SOLUBLE CAMPTOTHECIN ANALOG - 1996

      Critical reviews in oncology/hematology
    33. CANAL P; GAY C; DEZEUZE A; DOUILLARD JY; BUGAT R; BRUNET R; ADENIS A; HERAIT P; LOKIEC F; MATHIEUBOUE A
      PHARMACOKINETICS AND PHARMACODYNAMICS OF IRINOTECAN DURING A PHASE-IICLINICAL-TRIAL IN COLORECTAL-CANCER

      Journal of clinical oncology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 16/01/21 alle ore 09:51:53